Bimagrumab for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 14 Nov 2022: Trial registered, NCT05616013
  2. 16 Nov 2022: Trial started, NCT05616013
  3. 16 Oct 2024: Trial registered, NCT06643728
  4. 21 Oct 2024: Trial started, NCT06643728

The trials

NCT05616013: Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

State
Completed
Phase
Phase 2
People
507 taking part
Started
16 Nov 2022
Primary completion
16 May 2024
Arms
10/30 mg/kg Bimagrumab, 30 mg/kg Bimagrumab
Results
Posted on the registry
  1. 14 Nov 2022: Trial registered
  2. 16 Nov 2022: Trial started
  3. 14 Jun 2025: Trial completed
  4. 18 Jul 2025: Trial results posted

NCT06643728: A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

State
Completed
Phase
Phase 2
People
252 taking part
Started
21 Oct 2024
Primary completion
16 Jan 2026
Arms
Part A: Bimagrumab Dose 2 + Tirzepatide Placebo, Part A: Bimagrumab Dose 1 + Tirzepatide Dose 1, Part A: Bimagrumab Dose 1 + Tirzepatide Dose 2, Part A: Bimagrumab Dose 2 + Tirzepatide Dose 2, Part B: Bimagrumab Dose 2 (no titration) + Tirzepatide Dose 1, Part B: Bimagrumab Dose 2 (fast titration) + Tirzepatide Dose 1, Part B: Bimagrumab Dose 2 (slow titration) + Tirzepatide Dose 1, Part B: Bimagrumab Dose 1 + Tirzepatide Placebo
Results
None posted
  1. 16 Oct 2024: Trial registered
  2. 21 Oct 2024: Trial started
  3. 27 Oct 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.